Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 449 • 2017 ACR/ARHP Annual Meeting
Medical Bugs for Pain Relief in Patients with Rheumatoid Arthritis, a Systematic Review
Rongqiang Zhang¹, Puwei Yuan², Jia Li³, Bo Dong¹, Wulin Kang³, Stephanie Hyon⁴, Raveendhara R. Bannuru⁵, William F. Harvey⁴ and Chenchen Wang⁴, ¹Shaanxi University of Chinese Medicine, Xianyang 712046, China, Xianyang, China, ²Shaanxi University of Chinese Medicine, Xianyang 712046, China, XianYang, China, ³Shaanxi University of Chinese Medicine, Xianyang, China, ⁴Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, ⁵Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: Medical bugs, a term used to describe insects and arthropods for medical treatment, have been widely used in the past centuries for pain relief.…
Abstract Number: 2462 • 2017 ACR/ARHP Annual Meeting
Tapering TNF Inhibitors in Rheumatoid Arthritis: A Retrospective Study
Ayse Hacioglu¹, Gulen Hatemi², Sinem Nihal Esatoglu², Yesim Ozguler², Serdal Ugurlu¹, Emire Seyahi², Melike Melikoglu², Izzet Fresko², Huri Ozdogan², Sebahattin Yurdakul² and Vedat Hamuryudan², ¹Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Current guidelines on RA treatment recommend tapering of biologic DMARDs for patients in persistent remission. Methods: In this retrospective study we used the hospital…
Abstract Number: 455 • 2017 ACR/ARHP Annual Meeting
Analysis of Real-World Treatment Patterns in a Matched Sample of Rheumatology Patients with Continuous Infliximab Therapy or Switched to Biosimilar Infliximab
Lorie A. Ellis¹, Ismail Simsek², Lin Xie³, Adesuwa Ogbomo³, Dennis Parenti⁴, Kavitha Goyal⁴ and Yusuf Yazici⁵, ¹Janssen HECOR Immunology, Horsham, PA, ²Guven Hospital, Ankara, Turkey, ³STATinMED Research Inc., Ann Arbor, MI, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Biosimilar infliximab (CT-P13) was first approved in Europe in 2013.This study compared treatment (tx) patterns of Turkish pts with a diagnosis of rheumatoid arthritis(RA)…
Abstract Number: 2863 • 2017 ACR/ARHP Annual Meeting
Serum Proteomic Signatures Predict Relapse in Rheumatoid Arthritis Patients Undergoing DMARD Withdrawal
Liam O'Neil¹, Victor Spicer², Carol A Hitchon², Juergen Rech³, Axel J. Hueber⁴, John Wilkins², Hani El-Gabalawy¹ and Georg Schett³, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁴Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Early and targeted treatment strategies have led to increasing numbers of patients with RA achieving sustained clinical remission. If and when to taper Disease…
Abstract Number: 471 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?
Adeeba Al-Herz¹, Aqeel Ghanem², Khulood Saleh³, Adel Al-Awadhi⁴, Waleed Al-Kandari³, Eman Hasan⁵, Mohammad Hussain⁵, Ibrahim Nahar², Fatemah Abutiban⁶, Ahmad Alenizi⁶, Yaser Ali², Ali Aldei¹, Hebah Alhajeri², Sawsan Hayat², Ahmad Khadrawy³, Ammad Fazal³, Khaled Mokaddem¹, Agaz Zaman², Ghada Mazloum², Youssef Bartella¹, Sally Hamed¹, Ramia Alsouk⁶ and Ahmed Al-Saber⁷, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ³Rheumatology, Farwania Hospital, Farwania, Kuwait, ⁴Faculty of Medicine, Kuwait, Kuwait, ⁵Al-Amiri Hospital, Kuwait city, Kuwait, ⁶Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁷Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: Patients with rheumatoid arthritis (RA) may fail to respond to biologic therapy. We study patients who are resistant to different classes of biologic agents…
Abstract Number: 516 • 2017 ACR/ARHP Annual Meeting
Efficacy of Adding Iguratimod Therapy in Rheumatoid Arthritis　Patients Who Had Inadequate Response to Biologic Dmards
Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan
Background/Purpose: Iguratimod (IGU) was approved in June 2012 and recommended by JCR guideline 2014 in the treatment of rheumatoid arthritis (RA). Although there have been…
Abstract Number: 863 • 2017 ACR/ARHP Annual Meeting
Functionally Distinct Pathogenic Subsets of Fibroblasts Exist within the Inflamed Synovial Membrane and Mediate Specific Aspects of Inflammatory Disease Pathology
Adam Paul Croft¹, Joana Campos², Loriane Savary², Emma Bishop², Jason Turner¹, Guillaume Desanti², Francesca Barone³, Andrew Filer³ and Chris Buckley², ¹Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Fibroblasts are key effector cells in the persistence of synovial inflammation and joint damage. It is not yet known whether specific subsets of synovial…
Abstract Number: 1030 • 2017 ACR/ARHP Annual Meeting
Healthcare Service Utilization and Costs of Certolizumab Pegol Versus Infliximab Treatment in Patients with Rheumatoid Arthritis
Joseph Tkacz¹, Edward Lee², Robert Low², Jeffrey Stark², Mohamed Yassine² and Brenna Brady¹, ¹Health Analytics LLC, Columbia, MD, ²UCB Pharma, Smyrna, GA
Background/Purpose: Prior retrospective claims analyses examining rheumatoid arthritis (RA) treatment costs have shown infliximab (IFX) to be costlier than certolizumab pegol (CZP) across all sites…
Abstract Number: 1079 • 2017 ACR/ARHP Annual Meeting
Treat to Target Adherence Measurement Tool Performance in Rheumatoid Arthritis
Rodrigo Garcia Salinas¹, Sebastian Magri² and Facundo Salvatori³, ¹Section of Rheumatology, Hospital Italiano de La Plata, Buenos Aires, Argentina, La Plata, Argentina, ²Section of Rheumatology, Hospital Italiano de La Plata, La Plata, Argentina, ³Rheumatology, Hospital Italiano de La Plata, La Plata, Argentina
Background/Purpose: The purpose of the T2T approach in RA is to achieve remission or LDA according to results from objective activity measurements. This strategy has…
Abstract Number: 1333 • 2017 ACR/ARHP Annual Meeting
Mortality of Tumor Necrosis Factor Transgenic Arthritic Mice with Interstitial Lung Disease Occurs with Pulmonary Arteriole Thickening and Right Ventricular Hypertrophy but Is Not Associated with Inducible Nitric Oxide Synthase Dependent Inflammatory Cell Infiltration
Richard Bell¹, Emily Wu^1,2, Homaira Rahimi³ and Edward Schwarz^1,4,5, ¹Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ²Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, ³Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY, ⁴University of Rochester, Rochester, NY, ⁵Univ of Rochester Med Ctr, University of Rochester School of Medicine and Dentistry, Rochester, NY
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) occurs in up to 15% of RA patients, whose median survival expectancy after diagnosis is only 2.6…
Abstract Number: 1349 • 2017 ACR/ARHP Annual Meeting
Treat to Target: What’s the Target?
Philip Dunn¹, Jonida Cote¹, Eric Newman² and Lester Kirchner¹, ¹Geisinger Medical Center, Danville, PA, ²Department of Rheumatology, Geisinger Medical Center, Danville, PA
Background/Purpose: The 2015 ACR RA treatment guidelines focus on measuring disease activity and provide a guideline driven treat to target strategy. We hope to understand…
Abstract Number: 1418 • 2017 ACR/ARHP Annual Meeting
The Value of Adalimumab Trough Levels and Clinical Assessments in Predicting Clinical Response in Patients with Established Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Josef S. Smolen¹, Nael Mostafa², Xin Huang², Peter Noertersheuser³, Ben Klünder³, Kun Chen², Jasmina Kalabic³, Iain Sainsbury², Ruud Oerlemans⁴, Stefan Florentinus⁴ and Gerd R. Burmester⁵, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie, Nederland, Hoofddorp, Netherlands, ⁵Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany
Background/Purpose: Low trough levels of the tumor necrosis factor inhibitor, adalimumab (ADL), and anti-ADL antibodies (AAA) were reported to be correlated with lack of response…
Abstract Number: 1425 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Patients with Rheumatoid Arthritis Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Philip J Mease¹, Neil Accortt², Mei Liu³, Sabrina Rebello³, Mahdi Gharaibeh² and David Collier², ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Amgen Inc., Thousand Oaks, CA, ³Corrona, LLC, Southborough, MA
Background/Purpose: Many treatment options are currently available to patients with rheumatoid arthritis (RA), including tumor necrosis factor inhibitors (TNFi’s). While combination therapy of TNFi’s or…
Abstract Number: 1703 • 2017 ACR/ARHP Annual Meeting
A Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation, Multi-Center Study of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells in Patients with Rheumatoid Arthritis and Incomplete Response to at Least One Tnfα Inhibitor
Suzanne Kafaja¹, Donna Skerrett², Silviu Itescu³ and Daniel E. Furst⁴, ¹Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ²Mesoblast Inc., New York, NY, ³mesoblast Inc., New York, NY, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Allogeneic STRO-3 immunoselected mesenchymal precursor cells (MPCs) derived from bone marrow of healthy donors are a potent, homogeneous cell population which can be activated…
Abstract Number: 353 • 2017 ACR/ARHP Annual Meeting
Patient Experiences of Rheumatoid Arthritis Models of Care: An International Survey
Cheryl L. Koehn¹, Kelly Lendvoy¹, Yue Ma², Linda Li³, Alison Hoens⁴, Marion Souveton⁵ and John M. Esdaile⁴, ¹Arthritis Consumer Experts, Vancouver, BC, Canada, ²Simon Fraser University, Burnaby, BC, Canada, ³Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ⁴Arthritis Research Canada, Richmond, BC, Canada, ⁵F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: Despite the global prevalence of rheumatoid arthritis (RA), there is no single model of care (MoC) and little is known about the RA patient…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].